HIGHLIGHTS
- who: Ashish Sharma from the India Associates, The University of Nevada, Reno School have published the article: Port delivery system with ranibizumab (Susvimo) recall- What does it mean to the retina specialists, in the Journal: (JOURNAL) of August/31,/2022
- future: This drastically improved the incidence of vitreous hemorrhage in the later part of phase 2 and future trials. Unlike the brolucizmuab inflammation safety issues which cannot mitigated it is hoped that since Susvimo has undergone a voluntary recall and it is related to quality testing this will be rectified in the near future and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.